Xcout IntelResverlogix competitors & alternatives
The 12 closest competitors and alternatives to Resverlogix among biotech companies — ranked by similarity to what Resverlogix actually does, not by market-cap band.
Subscribe to see Resverlogix’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Resverlogix
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Resverlogix at a glance
Resverlogix is a biotech company headquartered in Calgary, Canada. It is publicly listed (RVX) with a market capitalisation of $23.6M. Xcout tracks 2 named people at Resverlogix, including Donald McCaffrey (Co-Founder).
Resverlogix leadership
- Donald McCaffreyCo-Founder
- Norman WongCo-Founder
Top 12 Resverlogix competitors
Ranked by semantic similarity — how close each company is to Resverlogix by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Biotechnology
Evrys Bio, LLC is a biotechnology company developing first-in-class therapeutics designed to treat a broad spectrum of viral infections and prevent drug resistance. The company utilizes allosteric, small molecule SIRT2 modulators that target host cells to suppress viral infections and shift metabolic reprogramming.
Similar biotech company
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Biotechnology
Thryv Therapeutics Inc., formerly known as LQT Therapeutics Inc., is a privately owned clinical-stage biotechnology company based in Montreal, Quebec, Canada. The company pioneers targeted therapeutic treatments addressing serious medical conditions. Operating out of its downtown Montreal headquarters, the firm manages dedicated research and development programs.
Life Sciences
Rejuveron Life Sciences AG is a biotechnology company headquartered in Schlieren, Switzerland, focused on developing innovative therapeutics and therapies for aging-related diseases and longevity.
Biotechnology
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Biotechnology
Liminal BioSciences is a biopharmaceutical company headquartered in Laval, Quebec, Canada, focused on developing innovative small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases.
Biotechnology
Aegle Therapeutics Corp. is a clinical-stage biotechnology company headquartered in Miami, Florida, with additional operations in Woburn, Massachusetts. The company is a leader in developing novel extracellular vesicle therapies to treat various diseases and disorders.
Biotechnology
ResNovas Therapeutics is a biotechnology and therapeutics company headquartered in Alameda, California, operating within the San Francisco Bay Area.
Biotechnology
Recognify Life Sciences is a clinical-stage biotechnology company located in California, focusing on developing treatments for cognitive impairment associated with central nervous system disorders.
Similar biotech company
Sernova Corp. is a Canadian firm, established in 1998 and headquartered in London, that specializes in advanced regenerative medicine therapeutics and is currently in its clinical development phase. The company's primary objective is to innovate and bring to market novel treatments, with a core focus on its unique "Cell Pouch" system. This sophisticated medical device is engineered to create a highly vascularized environment within the body, enabling the successful implantation and integration of therapeutic cells. Once integrated, these cells are designed to continuously release vital proteins or hormones, providing a long-term approach to managing debilitating chronic conditions like diabetes, hemophilia, and thyroid disease. Accompanying the Cell Pouch are related technologies that involve specialized therapeutic cells and methods to shield them from the body's immune response. Sernova actively collaborates with AgeX Therapeutics, Inc. to develop immune-protected therapeutic cells and maintains a research partnership with the University of Miami to further refine its Cell Pouch cell therapy platform.
Biotechnology
Inversago Pharma is a Canadian biotechnology company developing peripherally restricted CB1 receptor antagonists/inverse agonists for metabolic, fibrotic, and related diseases. Its drug-development programs are intended to serve patients with conditions such as obesity, metabolic syndrome, and diabetic kidney disease.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Resverlogix and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Resverlogixand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →